Table 2 Characteristics of patients diagnosed with gout or asymptomatic hyperuricemia
| Â | Patients with ULT treatment | Patients with no ULT treatment | All | |||
|---|---|---|---|---|---|---|
| Â | Age | Â | Â | Â | Â | |
Total (n = 97) | 0–5 years (n = 1) | 6–11 years (n = 10) | 12–18 years (n = 86) | Total (n = 179) | Total (n = 276) | |
Sex, n (%) | ||||||
 Male | 83 (85.6) | 1 (100.0) | 6 (60.0) | 76 (88.4) | 126 (70.4) | 209 (75.7) |
 Female | 14 (14.4) | 0 (0.0) | 4 (40.0) | 10 (11.6) | 53 (29.6) | 67 (24.3) |
Comorbidity, n (%) | ||||||
 Kidney disease | 46 (47.4) | 0 (0.0) | 7 (70.0) | 39 (45.3) | 50 (27.9) | 96 (34.8) |
 Cardiovascular disease | 26 (26.8) | 1 (100.0) | 4 (40.0) | 21 (24.4) | 37 (20.7) | 63 (22.8) |
 Metabolic syndrome | 32 (33.0) | 0 (0.0) | 2 (20.0) | 30 (34.9) | 86 (48.0) | 118 (42.8) |
 Down syndrome | 6 (6.2) | 0 (0.0) | 0 (0.0) | 6 (7.0) | 9 (5.0) | 15 (5.4) |
Treatment and drug use, n (%) | ||||||
 Dialysis | 2 (2.1) | 0 (0.0) | 0 (0.0) | 2 (2.3) | 0 (0.0) | 2 (0.7) |
 Cardiovascular disease drug | 5 (5.2) | 0 (0.0) | 4 (40.0) | 1 (1.2) | 4 (2.2) | 9 (3.3) |
 Diuretic drug | 8 (8.2) | 1 (100.0) | 3 (30.0) | 4 (4.7) | 5 (2.8) | 13 (4.7) |
 β blocker | 5 (5.2) | 0 (0.0) | 2 (20.0) | 3 (3.5) | 2 (1.1) | 7 (2.5) |
 Ca antagonist | 6 (6.2) | 0 (0.0) | 1 (10.0) | 5 (5.8) | 2 (1.1) | 8 (2.9) |
 ACEI and/or ARB | 24 (24.7) | 1 (100.0) | 3 (30.0) | 20 (23.3) | 8 (4.5) | 32 (11.6) |
 Antihyperlipidemic drug | 7 (7.2) | 0 (0.0) | 0 (0.0) | 7 (8.1) | 7 (3.9) | 14 (5.1) |
 Antidiabetic drug | 1 (1.0) | 0 (0.0) | 0 (0.0) | 1 (1.2) | 4 (2.2) | 5 (1.8) |
 Immunosuppressant | 9 (9.3) | 0 (0.0) | 5 (50.0) | 4 (4.7) | 9 (5.0) | 18 (6.5) |
 Vitamin D | 7 (7.2) | 0 (0.0) | 2 (20.0) | 5 (5.8) | 6 (3.4) | 13 (4.7) |